Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seco and ye shall find
Also a gap at 1.73 on the 5 day chart, 6/3/2022
3/15/22
We’ll see if they take advantage of the opportunity, need to close slightly below 80 on the Williams indicator and then rip higher
Big day possible at close into tomorrow and going forward, chart opportunity is perfectly set for major gains, V for victory
Seac and ye shall find
Selling pressure is decreasing to zero then we should see a reversal higher, hopefully news coupled with the conference presentations this week
One day closer to the resource estimate
Potential is there for big gains
What a great chart opportunity for this company right now
Wall Street powers that be chose AWS because they need a dominant crypto gift card system which is separate and apart from the coinbases of the world which people do not trust anymore. Broken trust is why crypto is declining, too many hacks and thefts, this gift card can be a breath of fresh air into what has been corrupted. We’ll see, they have the opportunity.
Back to 2.34 gap before opportunity to surge higher again
.1850 is the gap, not .1580
41 million in volume the selling shareholder of 6 million is certainly out of shares, especially with the CEO 2 million purchase, now that shareholder is not an obstacle for higher share prices going forward
.95 gap filled, opportunity for major turn higher again
Looking at 1.06 on Fangage completion this month, a slight dip, then merger announcement sends SP moon.
“8:00a ET 6/7/2022 - BusinessWire
Cybin Acquires DMT Clinical Study from Entheon Biomedical
-- Phase 1 study evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and will inform clinical path forward --
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics(TM)", today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine ("DMT") study (the "Acquisition") from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon") to accelerate the clinical development path for CYB004, Cybin's proprietary deuterated DMT molecule for the potential treatment of anxiety disorders.
The Phase 1 EBRX-101 study, now named CYB004-E, is being conducted in the Netherlands at the Centre for Human Drug Research, a leading independent foundation specializing in innovative early-stage clinical drug research, in 50 healthy volunteers who smoke tobacco - making it the largest Phase 1 DMT clinical study conducted to date. Pending the close of the Acquisition, the CYB004-E study is expected to yield essential safety and dosing optimization data and will replace Cybin's planned pilot study for CYB004 that was expected to commence in the third quarter of 2022. Entheon will continue to support the CYB004-E study and act as external consultants to Cybin.
"The most precious commodity in drug development is time and acquiring this robust Phase 1 study already underway potentially accelerates the CYB004 development program by approximately nine months. The PK findings from the CYB004-E study should also help to inform the clinical path forward for this innovative and proprietary molecule," said Doug Drysdale, Chief Executive Officer of Cybin. "This transaction also provides Cybin with access to a world-class research foundation and the privilege to work with the Entheon team, who offer a wealth of knowledge and expertise in this psychedelic class."
The purchase price of the Acquisition is $1,000,000 (CAD), a portion of which will be a deposit with the balance payable on closing of the Acquisition. Up to an additional $480,000 (CAD) is payable for consulting services to be provided by Entheon for up to twelve months following the closing of the Acquisition. Pursuant to the Acquisition the Company will also enter into a data license agreement with Entheon that will permit Entheon to access certain data to support the Entheon IQ program. The Company expects the Acquisition to close within 30 days, subject to the completion of certain conditions and obtaining all necessary approvals.
"With our recent IND filing for CYB003, we are quickly becoming a multi-program clinical-stage company with four sponsored human trials underway in 2022. This is especially meaningful to our work to bring our innovative psychedelic-based therapies to people in need as quickly as possible. This is a truly exciting time for Cybin," concluded Drysdale.
About the CYB004-E Study
The CYB004-E study is an adaptive, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics ("PK") and pharmacodynamics ("PD") of a target-controlled intravenous infusion of DMT in healthy smokers.
Primary Objectives:
Evaluate the safety of increasing doses of a single dose continuous DMT infusion over 90 minutes;Characterize the PK of a single dose DMT administered continuously over 90 minutes;Characterize the PD of a single dose DMT administered continuously over 90 minutes; andEstablish the minimum DMT dose required to produce a psychedelic effect.
Pending results from the CYB004-E study, Cybin plans to evaluate CYB004 delivered via intravenous ("IV") and via inhalation to determine the clinical path forward. Based on preclinical results reported by Cybin in April 2022, inhaled CYB004 demonstrated:
Approximately 2000% improved bioavailability compared with orally administered DMT, which is known to have limited to no oral bioavailability;Approximately 41% improved bioavailability compared with inhaled DMT;Approximately 300% longer duration of effect when compared with IV DMT, indicating potential to extend therapeutic window; andRapid onset of effect and similar low variability equivalent to IV DMT.
CYB004 is a new chemical entity for which a patent was issued by the U.S. Patent and Trademark Office in February 2022. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT. The composition of matter patent is expected to expire in 2041 before consideration of any patent term extensions.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.”
https://www.businesswire.com/news/home/20220606006028/en/
Dip to .2150 gap and rip
Here is another 6 month consolidation complete, opportunity is there for an major increase this week
Good price imo to jump back in before a large increase in SP
1.30 gap fill soon
Resource estimate being created, lithium will continue to be in high demand.
Stock has a major chance here to make gains
No I note gaps on stocks that should therefore decrease and I note when a stock has no gaps and should therefore release news and increase of economic conditions make sense. Taug has an opportunity this week for major gains if anyone wants to look at the 6 month chart.
6 month chart time to rise
Gap filled perfect time to announce news
They also could continue to decide to deny this custodian pink and require more documents, doubt it this close to GOT tho.
What is that link
I guess gas prices on wed thur and Fri were back at normal levels to see this share price drop toward the gap. Odd price action imo.
Price shouldn’t have dropped the last three days then if it was all about gas prices
Gap 5.60
Time to moon
.1580 is key price for news on wallet, company waiting for all gaps to fill first before major increase
Thursday is the opportunity, till then 3 day dip and rip
Quadruple bottom on the MACD, chance for a great week
“7:00a ET 5/13/2022 - Globe Newswire
FindThisBest Selects Tauri-Gum as The #1 Best Kosher Chewing Gum in the Overall Marketplace
EQNX::TICKER_START (Other OTC:TAUG),(OTC US:TAUG), EQNX::TICKER_END viaNewMediaWire - Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"), a New York-based diversified Life Sciences and Pharmaceutical Development Company, today announced that the online shopping research platform, FindThisBest (www.findthisbest.com), has named Tauri-Gum as the #1 best Kosher certified chewing gum in the overall marketplace. FindThisBest shortlisted its Top 24 choices of Kosher chewing gums, with Tauri-Gum finishing in 1st Place.
This Review evaluated 415 Kosher chewing gums and analyzed 28,015 customer reviews; it was completed on April 30, 2022.
Link to FindThisBest Kosher Chewing Gum Review:
https://www.findthisbest.com/best-chewing-gum/kosher
Other Kosher chewing gum brands named in this Review were: Elite, Simply Gum, Tootsie Roll Dubble Bubble, Mastika, Orbit, Fruidles, and Chewsy.
FindThisBest Editor's Notes:
During our Kosher chewing gum research, we found 415 kosher chewing gum products and shortlisted 24 quality products. We collected and analyzed 28,015 customer reviews through our big data system to write the kosher chewing gum list. We found that most customers choose kosher chewing gum with an average price of $13.
The kosher chewing gum are available for purchase. We have researched hundreds of brands and picked the top brands of kosher chewing gum, including the # 1 Pick: Tauri-Gum, Fruidles, Xylichew, ELITE, Simply Gum.
Link to FindThisBest:https://www.findthisbest.com
Tauri-Gum Products can be purchased through the following two E-Commerce Websites:
ABOUT FINDTHISBEST:
FindThisBest is an online platform that is based on cutting edge technology & helps you to find your relevant seller in just a few clicks. You can perform an Amazon seller search & search for the sellers by categories on this site & later on add their names or nicknames to find a particular seller. Moreover, it provides a list of top-rated Amazon sellers which is updated every month based on their performance & reviews.
On FindThisBest, you'll find a list of top sellers that we measure for shoppers to choose from while shopping based on their operational results. Each month, the rankings are updated and it brings you the top 1,000 sellers. The ranking engine takes the sales figures of a seller, monthly feedback, favorable and negative scores, and more into account while making this list.
So if you are looking for a seller on Amazon, give it a try to FindThisBest!”
“6:30p ET 5/6/2022 - Globe Newswire
Jourdan Engages Stanford & Turner for Assistance with Marketing Campaign
EQNX::TICKER_START (TSX-V:JOR),(OTC US:JORFF),(Other OTC:JORFF),(Boerse Stuttgart - Freiverkehr:2JR1), EQNX::TICKER_END JOURDAN RESOURCES INC. (TSXV: JOR; OTCQB: JORFF) ("Jourdan" or the "Company") announces today that it has entered into a marketing services agreement with Stanford & Turner Marketing Group ("Stanford"). Stanford is a digital media marketing company that provides a combination of content development, web development, media buying and distribution, and reporting and optimization to Jourdan. Pursuant to the agreement, Stanford will assist Jourdan in enhancing its visibility with potential investors through a digital marketing campaign for a total cost of US$75,000 over a three-month period commencing May 9, 2022, and US$25,000 per month on a month-to-month basis thereafter. Stanford is an arm's length party from the Company and principally operates out of Los Angeles, California. As of the date of this press release, neither Stanford nor any of its directors and officers own any interest, directly or indirectly, in the securities of the Company. The appointment of Stanford is subject to approval by the TSX Venture Exchange.
”
May 9 to June 9 is one month, what has this marketing campaign done for $75,000? Will we see some news so the marketing company can help enhance the share price?
Robotics stock down 80 - 90 % in 6 months in an economy that is increasingly automating processes
Two months since Matrix release:
“9:26a ET 4/7/2022 - Benzinga
VirnetX Launches Matrix Product
Combats Threats and Protects Businesses and Employees from Cyberattacks
ZEPHYR COVE, Nev., April 7, 2022 /PRNewswire/ -- VirnetXâ?¢ Holding Corporation (NYSE:VHC), an Internet security software and technology company, today announced the launch of VirnetX Matrix to secure private access to Internet applications, services and critical infrastructure. VirnetX Matrix enforces access policy controls and enables real-time network management to protect cloud or on-premises applications from threats.
VirnetX Matrix safeguards applications and contemporary remote workforce from sophisticated hackers and mitigates threats by enabling corporate applications to be invisible from unauthorized users. Matrix utilizes VirnetX One, a software-as-a-service (SaaS) platform that secures communications and protects applications, services, devices and infrastructure from cyber-attacks regardless of network or location. VirnetX One implements a modern Zero Trust architecture built on VirnetX's patented Secure Domain Name Technology.
"Threats to Internet applications and hybrid workforce are at an all-time high," said Kendall Larsen, VirnetX CEO and President. "While legacy security solutions lack complete visibility and protection, VirnetX Matrix delivers Internet security professionals a powerful solution to secure applications and services and thwart these evolving nefarious attacks."
With the proliferation of Bring Your Own Device (BYOD) policies, government facilities, healthcare networks, and telecommuting being the new reality, VirnetX Matrix provides remote teams with a comprehensive security posture. According to industry experts, there will be an estimated 24 billion interconnected devices by 2050. VirnetX Matrix provides seamless and secure access to interconnected devices and corporate applications, regardless of location, network or device.
Key features of VirnetX Matrix include:
Mitigate Attacks â?? Matrix offers protection from external threats including hackers, phishing, misconfigurations, and denial of service attacks. It limits lateral movement across network applications and services by threat actors.
Trusted Access â?? Matrix authenticates user access and secures applications and services using patented Secure Domain Name Technology. With Matrix, users can manage access, apply access policies in real-time, and easily understand who has access to information.
Cloud Security â?? Matrix allows users to easily secure applications in the cloud, on-premises or across hybrid deployments without impacting deployment or user experience. The cloud-based dashboard allows users to manage their applications, control access in real-time, and gain visibility into the users and devices that have access.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”
32.89 gap